PPT-ADVANCED PROSTATE CANCER: BONE ISSUES AND METASTASES

ADVANCED PROSTATE CANCER BONE ISSUES AND METASTASES Samuel Denmeade MD Professor of Oncology Urology and Pharmacology The Johns Hopkins University School of Medicine Castratesensitive NonMetastatic. Prostate Cancer . Congress. Meeting in . a. Box. Screening for Prostate Cancer – . The PSA Controversy. Leonard G. . Gomella. , MD. US Preventive Services Task Force . (USPSTF) Screening Recommendations. Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. Paul . Sieber. MD FACS. Lancaster Urology. ADT Clinic. Why . 1. Consistency of care . . 2. Improved outcomes. . 3. Better economics. What does it take. 1. Discipline. of the Prostate Gland. Dr. . Kaveh. . Mehravaran. Urologist, Fellowship of . Endourology. & Laparoscopy. Hasheminejad. Hospital. BENIGN PROSTATIC HYPERPLASIA. Incidence & . Epidemiology. BPH is the most common benign tumor in men, and . The second most common cancer diagnosed in men. The incidence increase with age very rare before age of 40, more in western countries particularly Scandinavian countries (low light exposure), and black men are at greatest risk. When to Image Based on . Choosing . Wisely. ®. . and ACR Appropriateness . Criteria. ®. What Is R-SCAN?. 2. C. ollaborative activity . for referring clinicians and radiologists to improve patient . Presentation. . by. Caterina Gentili, . PhD candidate . 27. th. September 2018 – CAR weekly . Background. Background. growing population . of . PCa. survivors. Background. growing population . of . Amar Mohee. Consultant Urological Surgeon. Manchester Royal Infirmary. Greater Manchester . Cancer. Prostate Cancer. Prostate . cancer: most . common cancer in . men. 47000/year (129 new diagnosis/day). . By Dr. . Hiralal. . Chaudhari. M.B.B.S., D.N.B. (General Surgery). D.N.B. (Urology). Azeez Farooki, MD. Attending Physician, Clinical Member. Memorial Sloan Kettering Cancer Center. New York, NY. Objectives. Elucidate the problem of aromatase inhibitor induced bone loss and increased risk of fractures in breast cancer. Francesco GIAMMARILE. « . Aut tace aut loquere meliora silentio.  ». Bone scan and F-Choline . Radionuclide treatment . Presentation Outline. Introduction. NO CONFLICT OF INTEREST. General aspects. Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . Victoria . Sinibaldi. , RN, MS, CS, CANP, BC. Daniel P . Petrylak. , MD. . Disclosures for . Ms. . Sinibaldi. No financial interests or affiliations to disclose. Disclosures for Dr . Petrylak. Consulting Agreements. By: Ishan Parikh. Symptoms. Be on the look out for…. “stop-and-go” flow of urine. Sudden urges to urinate. Frequent urination (esp. at nights). Trouble starting urination. Trouble with emptying bladder completely.